Maybe that stat is only 20% of drugs entering phase 2 become commercial. Hence many pass phase two, but then fail phase 3 or have safety issue or are not commercial viable etc. No such problems for ftt, so long as they pass this phase 2 imho.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025